An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients with Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Related studies linked through entity extraction aliases.